Delivery Order SPE2DB22D9151-SPE2DB25FM8GH

Award Date 4/10/25
Potential Completion Date 5/1/25
Potential Value $5.1K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract is for the delivery of XOLAIR 300 MG/2 ML AUTOINJECT 2ML, with a ceiling value of $5,136.69 and a completion date of May 8, 2025. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue firm...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $51,366.90 contract is for the delivery of XOLAIR 300 MG/2 ML AUTOINJECT 2ML, with an ultimate completion date of October 21, 2024. DMS Pharmaceutical Group holds a $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the DLA to issue firm...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of XOLAIR 300 MG/2 ML AUTOINJECT 2ML, with a ceiling value of $3,424.46 and a period of performance through May 9, 2025. DMS Pharmaceutical Group holds a larger indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $5,136.69, is for the delivery of 4567089038 XOLAIR 300 MG/2 ML AUTOINJECT 2ML, a specialized pharmaceutical product. The contract has an ultimate completion date of February 20, 2025. DMS Pharmaceutical Group Inc. holds a significant single-award Indefinite...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of XOLAIR 300 MG/2 ML AUTOINJECT 2ML, a specialized pharmaceutical product, with a ceiling value of $6,848.92 and a period of performance through January 28, 2025. DMS Pharmaceutical Group Inc. holds a significant single-award Indefinite Delivery...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $6,413.70 contract is for the supply of 4567618432 XOLAIR 300 MG/2 ML AUTOINJECT 2ML, with a period of performance through April 1, 2025. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the DLA to issue firm fixed-price delivery...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $3,424.46 firm fixed-price contract is for the supply of 4566380230 - XOLAIR 300 MG/2 ML AUTOINJECT 2ML, a specialized pharmaceutical product. The contract has a period of performance through November 27, 2024. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $1,712.22 contract is for the delivery of XOLAIR 150 MG/ML AUTOINJECTORML, a specialized pharmaceutical product, with a period of performance through January 9, 2025. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $3,424.46 contract is for the delivery of Xolair 300 mg/2 ml autoinjector units, with a period of performance through January 9, 2025. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $3,424.46 contract is for the delivery of 4566894752 - XOLAIR 300 MG/2 ML AUTOINJECT 2ML, with a completion date of January 30, 2025. DMS Pharmaceutical Group holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999...
  • SPE2DB22D9151
    Indefinite Delivery Contract
  • SPE2DB22D9151-SPE2DB25FM8GH
    Delivery Order

This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract has a ceiling value of $5,136.69 and covers the delivery of XOLAIR 300 MG/2 ML AUTOINJECT 2ML pharmaceutical products. The contract has a period of performance through May 1, 2025.

DMS Pharmaceutical Group Inc. holds a larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026. This IDC enables the DLA to issue delivery orders for a comprehensive range of pharmaceutical items, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the medical supply needs of military health facilities worldwide. The current delivery order is not designated as a set-aside contract.

Generated 7/17/25, 6:00 PM